References in periodicals archive ?
Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population.
The renin-angiotensin-aldosterone system (RAAS) carries out multiple functions that are essential for blood pressure (BP) regulation, water and salt balance, and tissue growth control under physiologic conditions, and it plays a pivotal role in the pathophysiology of cardiovascular and renal disease.
Because renin-angiotensin-aldosterone system (RAAS) activation is known to play an important role in atherosclerosis, and because RAAS inhibition may have a direct beneficial effect on the artery wall, the investigators sought to determine if aliskiren, a direct renin inhibitor, would slow progression of coronary atherosclerosis in these patients.
Inhibition of the renin-angiotensin-aldosterone system (RAAS) improves survival in patients with chronic advanced heart failure (4-6) and in high-risk patients after myocardial infarction (MI) (6-8).
The first thing to remember about blood pressure is that it is controlled by four interrelated systems: renal pressure natriuresis, the renin-angiotensin-aldosterone system, the sympathetic nervous system, and the calcium-dependent muscle tone in resistance blood vessels.
Interrelationships between the renin-angiotensin-aldosterone system and calcium homeostatic systems.
Patients were randomized to receive losartan (Cozaar) or placebo, both taken in addition to conventional anti-hypertensive therapy (but not including renin-angiotensin-aldosterone system antagonist medications).
Vitae Pharmaceuticals today announced results of a Phase I clinical study in healthy volunteers demonstrating the Company's lead compound, VTP-27999, significantly reduced the activity of the renin-angiotensin-aldosterone system (RAAS) in the kidney.
Objective: To examine the efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system (RAAS) among patients with type 2 diabetic kidney disease.
2]), elderly patients, and patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (eg, angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with low systolic blood pressure.